CAS NO: | 199807-35-7 |
包装 | 价格(元) |
10 mM * 1 mL in Water | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Cilengitide is a potent and selectiveintegrininhibitor for αvβ3and αvβ5receptor, withIC50values of 4 nM and 79 nM, respectively. | ||||||||||||||||
IC50& Target | IC50: 4/79 nM (αvβ3/αvβ5)[1]. | ||||||||||||||||
体外研究 (In Vitro) | Cilengitide (EMD 121974) is the αvβ3and αvβ5integrin receptor antagonist. In cell adhesion studies assessing the human melanoma M21 or UCLA-P3 human lung carcinoma cell lines, Cilengitide inhibits integrin-mediated binding to vitronectin with IC50s of 0.4 and 0.4 μM[1]. In vitro treatment of Cilengitide, at a concentration greater than 1 μM, shows concentration- and time-dependent cytotoxic effects[2]. | ||||||||||||||||
体内研究 (In Vivo) | In nude mice bearing M21-L melanoma tumors, Cilengitide dose i.p. at 10, 50, and 250 μg three times per week demonstrate inhibition of tumor growth with a reduction in both tumor volume (55%, 75%, and 89%, respectively) and tumor weight (23%, 38%, and 61%, respectively), when compared to controls[2]. In the rat model studied, the systemic pharmacokinetics of i.p. Cilengitide are not affected by ILP with Cilengitide alone or ILP with Cilengitide plus Melphalan, TNF or both. Systemic Cilengitide levels reach around 20 μg/mL (approximately 35 μM) within 10 min of i.p. administration and continued to rise to approximately 40 μg/mL (approximately 70 μM) in the first hour. Thereafter Cilengitide levels in serum drop with an elimination half-life of 2.1 hr[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 702.68 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C29H41F3N8O9 | ||||||||||||||||
CAS 号 | 199807-35-7 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 25 mg/mL(35.58 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |